Blog
Theses, frameworks, and analysis from the XO Medtech team — on manufacturing, strategy, and AI in the device industry.

Claude for Manufacturing: How Medical Device CDMOs and Contract Manufacturers Can Use It
How medical device contract manufacturers, CDMOs and suppliers can use Anthropic's new Claude for Manufacturing: draft quotes and NCRs, with human review.

Medical device adverse events: what 5 years of FDA MAUDE data says about 16 of the largest OEMs
Sixteen of the largest device makers are tied to 4.8 million FDA adverse event reports in five years. Each file has its own failure signature, and it is legible.

Q3 SBIR/STTR medical device awards: 67 grants, $57.9M, and a six-month hole
NIH issued 67 SBIR/STTR medical device awards worth $57.9M in Q3 2026 through August 11, following two straight quarters with zero awards. Full breakdown.

KKR's $5.7B blockbuster acquisition of Integer: the largest CDMO take-private deal ever
KKR is acquiring Integer for $5.7B, the largest public take-private of a medtech CDMO on record. The deal, both companies, and what private equity does next.

The Medtech Supplier Roll-Up: 276 Transactions Since 2020
A data review of 276 medtech supplier transactions since 2020: who is transacting, what is being bought, and what the deal count does and does not establish.

Q2 2026 medtech earnings are a contract-manufacturing demand map
Abbott, J&J and Intuitive just reported. Skip the stock moves — the real signal is new FDA filings, U.S. capacity build-outs, and supplier realignment.

Dual-energy ablation: the second wave of PFA adoption
Cardiac ablation switched from thermal to pulsed field in under two years. Dual-energy RF+PFA catheters are the second wave. Here's the adoption data and the forecast.

The CDMO who cracks carbon fiber catheter reinforcement will dominate
Sinopec just put T1000-grade carbon fiber into mass production. The material is here. The manufacturing know-how is not. That gap is the whole opportunity.